Patent application number | Description | Published |
20080242658 | Inhibitors of Iap - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I | 10-02-2008 |
20090005411 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 01-01-2009 |
20090069294 | Organic Compounds - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 03-12-2009 |
20100056467 | COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS - The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML. | 03-04-2010 |
20100324083 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 12-23-2010 |
20110251134 | COMBINATION OF (A) A DNA TOPOSOMERASE INHIBITOR AND (B) AN IAP INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a DNA topoisomerase inhibitor compound and (b) a compound that inhibits the caspase-9 inhibiting properties of an inhibitor of apoptosis protein (IAP) for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 10-13-2011 |
20110281845 | ORGANIC COMPOUNDS - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 11-17-2011 |
20110319614 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 12-29-2011 |
20120129895 | METHODS OF TREATMENT - The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. | 05-24-2012 |
20120207769 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 08-16-2012 |
20130085153 | COMBINATION OF AN IAP INHIBITOR AND A TAXANE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE - The invention provides a pharmaceutical combination comprising:
| 04-04-2013 |
20130217719 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 08-22-2013 |
20140024687 | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists - The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. | 01-23-2014 |